Where is UroMems located?

UroMems is headquartered in Grenoble, France.

How many employees does UroMems have?

As of Jul 31, 2026, the latest employee count at UroMems is 90.

Is UroMems a funded company?

UroMems is a funded company, having raised a total of $150M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of UroMems?

UroMems' latest funding was a $***** Series D round on May 14, 2026, with participation from 1 investor.

Where does UroMems rank among its competitors?

UroMems ranks 4th amongst 49 active competitors, of which 10 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Australis Scientific, which secured an undisclosed amount in May, 2026.

Who are the top competitors of UroMems?

UroMems' top competitors include Axonics, Amber Therapeutics and Valencia Technologies. Among them, Australis Scientific secured the most recent funding round in May, 2026.

UroMems - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of active implantable devices for urological incontinence. The device MyoElectroMechanical System is based on a technology where a patient‘s activity is measured in real-time through micro-sensors inside the implant into which algorithms are embedded; the system interprets data coming from the micro-sensors and computes the urethral pressure to apply.

Key Metrics

Founded Year

2011

Location

Grenoble, France

Stage

Series D

Total Funding

$150M in 8 rounds

Latest Funding Round

Series D, May 14, 2026, $*****

Investors

Financiere Arbevel & 17 more

Ranked

4^th among 49 active competitors

Employee Count

90 as on Jul 31, 2026

Similar Companies

Axonics & 60 more

View UroMems' full profile

UroMems has raised a total funding of $150M over 8 rounds. Its latest funding round was a Series D round on May 14, 2026 for $*****. 1 investor participated in its latest round. UroMems has 18 institutional investors.

Here is the list of recent funding rounds of UroMems:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 14, 2026	5927187	Series D	1722632	7381215	2833954	9722431
Jun 26, 2024	5349441	Series C	5262325	6892674	1036893	European Innovation Council & 6 more
Apr 08, 2021	8924889	Series B	1841347	9437557	Financiere Arbevel & 1 more	Wellington Partners Venture Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of UroMems's funding rounds and investors

The founders of UroMems is Stephane Lavallee.

Here are the details of UroMems' key team members:

Stephane Lavallee: Co-Founder of UroMems.
Contact Info: 1 email address

View details of UroMems's Founder profiles and Board Members

UroMems' employee count trend

UroMems has 90 employees as of Jul 26. Here is UroMems's employee count trend over the years:

Uncover UroMems' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of UroMems include Axonics, Amber Therapeutics and Valencia Technologies. Here is the list of Top 10 competitors of UroMems, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Axonics 2013, Irvine (United States), Acquired	Developer of a device to control urinary and bowel movement	$143M	Advent Life Sciences, Edmond de Rothschild ... & 9 others	66/100
2nd	Amber Therapeutics 2021, London (United Kingdom), Series A	Developer of bioelectrical therapies for functional disorders of the peripheral nervous system	$100M	New Enterprise Associates, F-Prime Capital ... & 5 others	59/100
3rd	Valencia Technologies 2011, Santa Clarita (United States), Acquired	Developer of a coin-sized pacemaker-like device for the treatment of hypertension	$56.9M	BMG, Lifeblood Capital & 1 others	59/100
4th	UroMems 2011, Grenoble (France), Series D	Developer of active implantable devices for urological incontinence	$150M	BNP Paribas, b2venture & 16 others	59/100
5th	Levee Medical 2021, Durham (United States), Series B	Developer of urological devices for post-prostatectomy	$36.2M	-	57/100
6th	Affluent Medical 2011, Paris (France), Public	Developer of minimally invasive prostheses for structural heart disease, vascular therapy, and urology	$11.7M	Truffle Capital, Hayk Holding & 8 others	55/100
7th	Australis Scientific 2021, Fortitude Valley (Australia), Series A	Developing novel medical products that utilise neural modulation technologies	$6M	Rohto Group, ANDHealth	49/100
8th	Elidah 2014, Monroe (United States), Seed	Provider of non-invasive home device for strengthening pelvic muscles control	$2.02M	National Science Foundation, Connecticut Innovations ... & 2 others	41/100
9th	American Medical Systems 1972, Minnetonka (United States), Acquired	Medical solutions transforming lives through innovative technologies for healthcare professionals and patients	-	The Vertical Group, Thomas, McNerney & Partners ... & 1 others	41/100
10th	MyoPowers Medical Technologies 2004, Besancon (France), Series B	An implantable device for the treatment of urinary incontinence stress	$33M	Truffle Capital, Bpifrance & 4 others	40/100